Introduction {#S1}
============

The prevalence rates of atrial fibrillation (AF) and heart failure (HF) are growing in parallel because they share the same associated risk factors (obesity, [@B13]; [@B7], and aging, [@B6]). Nowadays, epicardial and pericardial adipose tissues play a central role in the development of both disorders ([@B27]; [@B24]). Epicardial adipose tissue (EAT) is localized around the heart and exerts a direct effect over the myocardium ([@B29]) and coronary arteries ([@B9]). In addition, in patients with HF, this fat tissue encloses β-adrenergic receptors ([@B5]) and exhibits higher catecholaminergic activity than subcutaneous adipose tissue (SAT) ([@B18]). Adrenergic activity promotes contractility and cardiotoxicity through reactive oxygen species production, which are involved in HF progression ([@B28]). Thus, the appearance of AF is common in these patients ([@B31]) and a consequent cause of HF progression. In adipose tissue, catecholamines upregulate lipolysis ([@B2]) and protein secretion ([@B5]). Some of the secreted proteins by epicardial fat are involved in fibrosis ([@B29]), which is considered an arrhythmogenic substrate ([@B19]). Since high levels of preoperative catecholamines are associated with postoperative AF ([@B1]), we wanted to identify epicardial fat predictors and mediators of AF, regulated by catecholamines, in patients with HF.

Materials and Methods {#S2}
=====================

Study Population {#S2.SS1}
----------------

We included patients from the following study ([@B5]) with HF diagnosis according to the recommendations of the European Society of Cardiology ([@B14]; [@B20]).

At admission, we divided the population into two groups according to the presence of previous AF. They were followed up for 5 years after open-heart surgery. New-onset paroxysmal or persistent AF during follow-up, excluding AF during the first 72 h after surgery, was recorded in a database.

Samples {#S2.SS2}
-------

The protocol was approved by the Galician Clinical Research Ethics Committee and carried out in accordance with the Declaration of Helsinki. Epicardial fat biopsies (0.1--0.3 g) were obtained before extracorporeal pulmonary circulation from 29 patients who signed informed consent and underwent open-heart surgery (valve replacement and/or coronary artery bypass graft). Blood samples from 12 patients were obtained in EDTA tubes before surgery. The exclusion criteria were previous heart surgery or severe infectious diseases. Instantaneously, the collected samples were placed in a sterile tube with phosphate-buffered saline solution that contained the following (in mM): 0.5 EDTA, 5 KCl, 10 HEPES, 2 MgCl~2~, 10 NaHCO~3~, 0.5 KH~2~PO~4~, 0.5 NaH~2~PO~4~, 10 glucose, 110 NaCl, and 0.16 CaCl~2~ (pH 7.4) (Sigma-Aldrich, San Luis, MO, United States). After washing samples three times, fat pads were split in 100 mg weight and cultured in 24-well plates with 0.5 ml of M199 medium (Lonza Biologics, Porriño, Spain). After 24 h, the medium was replaced, and fat pads were treated or not with isoproterenol at 1 μM for 6 h as previously described. Finally, the supernatants and fat tissues were collected and stored at −80°C until use.

Protein Identification {#S2.SS3}
----------------------

Secretomes from isoproterenol-treated fat pads of 11 patients were divided and filtrated by two different Amicon Ultra 0.5-ml columns (\>50 and 10--50 kDa) (Merck Millipore, Billerica, MA, United States). One fraction (named A) contained proteins heavier than 50 kDa, and the other fraction (named B) had proteins with a molecular weight between 10 and 50 kDa. Then, proteins were loaded and separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). After gels were stained with SYPRO Ruby (Bio-Rad), protein bands were digested with trypsin ([@B22]), and peptides were separated by reverse-phase chromatography. Gradient was achieved using a micro liquid chromatography system (Eksigent Technologies nanoLC 400, SCIEX) coupled to high-speed triple time-of-flight (TOF) 6600 mass spectrometer (SCIEX) with a micro flow source. The silica-based reverse-phase column was YMC-TRIART C18 150 × 0.30 mm with a 3-mm particle size and 120-Å pore size (YMC Technologies, Teknokroma), and the trap column was YMC-TRIART C18 (YMC Technologies, Teknokroma) with a 3-mm particle size and 120-Å pore size, switched online with the analytical column. A solution of 0.1% formic acid in water at 10 μl/min was loaded in the pump, and the micro-pump provided a flow rate of 5 μl/min, and it was operated under gradient elution (0.1% formic acid in water was mobile phase A and 0.1% formic acid in acetonitrile was mobile phase B). Peptides were separated using a 90-min gradient ranging from 2 to 90% mobile phase B (mobile phase A: 2% acetonitrile, 0.1% formic acid; mobile phase B: 100% acetonitrile, 0.1% formic acid). The injection volume was 4 μl, and data were acquired in a triple TOF 6600 system (SCIEX, Foster City, CA, United States) using a data-dependent workflow. Source and interface conditions were as follows: ion spray voltage floating (ISVF) 5,500 V, curtain gas (CUR) 25, collision energy (CE) 10, and ion source gas 1 (GS1) 25. The instrument was operated with Analyst TF 1.7.1 software (SCIEX, United States). Switching criteria were set to ions greater than a mass-to-charge ratio (*m*/*z*) of 350 and smaller than *m*/*z* 1,400 with a charge state of 2--5, mass tolerance of 250 ppm, and an abundance threshold of more than 200 counts (cps). Former target ions were excluded for 15 s. The instrument was automatically calibrated every 4 h using tryptic peptides from beta galactosidase as an external calibrant.

After MS/MS analysis, data files were processed using Protein Pilot TM 5.0.1 software from SCIEX which uses the algorithm Paragon^TM^ for database search and Progroup^TM^ for data grouping. Data were searched using a human-specific UniProt database. Then, identified proteins were grouped with the functional enrichment analysis tool (FunRich) in the presence/absence of AF or presence/absence of AF during follow-up. The design of the study is shown in [Figure 1A](#F1){ref-type="fig"}. Then, the selected proteins, after being identified, were tested on EAT and plasma to study the local or systemic changes ([Figure 1B](#F1){ref-type="fig"}).

![Study design. Epicardial adipose tissue (EAT) samples were obtained from 11 heart failure (HF) patients undergoing open-heart surgery. Samples were submitted to isoprenaline treatment. Secretome protein analysis was performed after a 5-year follow-up. Samples were classified according to atrial fibrillation absence (non-AF), AF onset, or previous AF. **(A)** Design for validating the identified proteins and their changes on tissue (local effect), secretome (paracrine effect) or plasma (systemic effect) **(B)**.](fphys-11-00620-g001){#F1}

Tissue Homogenization and Protein Analysis {#S2.SS4}
------------------------------------------

Stored fat tissues (100 mg) from 15 patients were lysed with 0.3 ml of RIPA buffer \[25 mM Tris--HCl, pH = 7.6, 150 mM NaCl, 1% (C~2~H~4~O) nC~14~H~22~O, 1% C~24~H~39~NaO~4~, and 0.1% NaC~12~H~25~SO~4~\]. All of them were from Sigma-Aldrich. Protease and phosphatase inhibitors (complete tables and PhosStOP easy pack from Roche Diagnostics, Basilea, CH) were added to RIPA buffer. Then, tissues were homogenized in a tissue lyser with steel beads (Qiagen, Hilden, DE) for 3 min at 30 Hz. Lysed tissues were centrifuged at 12,000 × *g* for 10 min, and the lipid layer was discarded. Proteins were purified with a 2-D Clean-Up Kit (GE Healthcare, Chicago, IL, United States) following the manufacturer's recommendations. Finally, 20 mg per tissue was separated with 8% SDS-PAGE and transferred to fluorescence polyvinylidene difluoride (PVDF) membranes (Merck Millipore, Burlington, MA, United States), at 300 mA for 90 min. The primary antibody against CD5L (1:1,000) was incubated in agitation overnight at 4°C (Santa Cruz Biotechnology, Dallas, TX, United States) after being blocked with 3% bovine serum albumin in Tris-buffered saline solution with Tween 20 (TBST), containing 20 mM Tris--HCl, pH = 7.6; 150 mM NaCl; and 0.% Tween 20. To remove the excess primary antibody, membranes were washed three times for 10 min with TBST. Finally, protein was detected in a fluorescence scanner (Typhoon FLA 9500, GE Healthcare) after membrane incubation with fluorescent anti-mouse secondary antibody Alexa 532 (Thermo Fisher). Densitometry of CD5L and IgG bands were determined by Quantity One software (Bio-Rad, Hercules, CA, United States). CD5L values were represented as the CD5L/IgG ratio in arbitrary units (a.u.). Plasma from 12 patients was obtained after blood centrifuging at 1,800 × *g*. Then, IgG and albumin were depleted with a mixed bed of Cibacron blue/protein A gel following the manufacturer's protocol (Thermo Scientific). At the end of the protocol, plasma was diluted seven times. After plasma filtration through 3-kDa columns (Sigma-Aldrich), it was diluted three times, and 10 μl was separated by SDS-PAGE and transferred to PVDF membranes that were incubated with CD5L antibody as described above. CD5L levels were referenced to values of the positive control (same sample on every western blot).

CD5L was also determined in secretomes and biopsies from three independent patients with or without isoproterenol treatment following the same previously described protocol.

Statistical Analysis {#S2.SS5}
--------------------

After protein identification, false discovery rate was performed using a nonlineal fitting method displaying only those results that reported ≥1% global false discovery rate ([@B23]; [@B26]). Clinical continuous variables were presented as mean ± standard deviation, and categorical variables were presented as frequency and percentage. Comparison between groups was performed with unpaired *t*-test or Pearson's χ^2^ test. Differences regarding two groups were performed by unpaired *t*-test analysis. All analyses were performed using SPSS 19.0. (Software SPSS Inc., Chicago, IL, United States).

Results {#S3}
=======

EAT-Released Proteins, After β-Adrenergic Stimulus, From HF Patients With and Without Previous AF Who Did or Did Not Develop AF {#S3.SS1}
-------------------------------------------------------------------------------------------------------------------------------

Proteomics studies were performed with samples from 11 patients (seven without AF and four with AF that developed during follow-up). The main clinical characteristics are detailed in [Table 1A](#T1){ref-type="table"}.

###### 

Clinical characteristics of proteomic study with respect to AF.

                                      **With AF (*n* = 4)**    **Without AF (*n* = 7)**
  ----------------------------------- ------------------------ ---------------------------
  Age years (SD)                      72 (3)                   68 (12); *p* = 0.501
  BMI, kg/m^2^ (SD)                   27 (5)                   31 (4); *p* = 0.126
  Heart rate (bpm)                    65 (10)                  76 (12); *p* = 0.186
  Gender (male/female)                1/3                      2/5; *p* = 0.898
  CAD (no/yes)                        3/1                      3/4; *p* = 0.303
  NYHA (I/II/III-IV)                  0/2/2                    2/4/1; *p* = 0.308
  T2DM (no/yes)                       3/1                      6/1; *p* = 0.658
  HTA (no/yes)                        2/2                      2/5; *p* = 0.477
  DLP (no/yes)                        3/1                      1/6; *p* = 0.044\*
  Aortic valve replacement (no/yes)   3/1                      2/5; *p* = 0137
  Mitral valve replacement (no/yes)   2/2                      6/1; *p* = 0.201
  LVEF (%)                            49 (15)                  61 (15); *p* = 0.223
  Diuretics (no/yes)                  3/1                      2/4; *p* = 0.197
  β-Blockers (no/yes)                 2/2                      3/3; *p* = 1.000
  Statins (no/yes)                    2/2                      2/4; *p* = 0.598
  ACEi (no/yes)                       2/2                      4/2; *p* = 0.598
  ARB (no/yes)                        2/2                      3/3; p = 1.000
  Antiarrhythmic class III (no/yes)   2/2                      6/0; *p* = 0.053
                                                               
                                      **With AFf (*n* = 3)**   **Without AFf (*n* = 4)**
                                                               
  Age years (SD)                      68 (6)                   68 (16); *p* = 0.975
  BMI, kg/m^2^ (SD)                   32 (4)                   31 (4); *p* = 0.699
  Heart rate (bpm)                    76 (5)                   75 (17); *p* = 0.976
  Gender (male/female)                0/3                      2/2; *p* = 0.147
  CAD (no/yes)                        2/1                      1/3; *p* = 0.270
  NYHA (I/II/III)                     0/3/0                    2/1/1; *p* = 0.140
  T2DM (no/yes)                       2/1                      4/0; *p* = 0.212
  HTA (no/yes)                        1/2                      1/3; *p* = 0.809
  DLP (no/yes)                        0/3                      1/3; p = 0.350
  Aortic valve replacement (no/yes)   1/2                      1/3; *p* = 0.809
  Mitral valve replacement (no/yes)   2/1                      4/0; *p* = 212
  LVEF (%)                            65 (6)                   58 (29); *p* = 0.567
  Diuretics (no/yes)                  0/2                      2/2; *p* = 0.221
  β-Blockers (no/yes)                 1/1                      2/2; *p* = 1.000
  Statins (no/yes)                    1/1                      1/3; *p* = 540
  ACEi (no/yes)                       2/0                      2/2; *p* = 221
  ARB (no/yes)                        1/1                      2/2; *p* = 1.000

BMI, body mass index; CAD, coronary artery disease; NYHA, New York Heart Association; T2DM, type 2 diabetes mellitus; HTA, hypertension arterial; DLP, dyslipidemia; LVEF, left ventricle ejection fraction; ACEi, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; AFf, AF during follow-up; AF, atrial fibrillation.

∗

p

\< 0.05 statistical significance.

After identifying proteins on each EAT secretome fraction, we found a mean of 328 ± 150 proteins with a molecular weight higher than 50 kDa (fraction A) and a mean of 55 ± 10 proteins with a molecular weight between 10 and 50 kDa (fraction B). Identified proteins on A and B per patient were analyzed by the FunRich tool. The Venn diagram determined 334 common proteins between EAT secretomes from patients with HF who did or did not develop new-onset AF during follow-up. However, only 29 EAT-secreted proteins were differentially identified between them ([Figure 2](#F2){ref-type="fig"}).

![Venn diagram determines common and differential identified proteins in epicardial adipose tissue (EAT) secretomes from patients who suffer or not from atrial fibrillation (AF) or will develop or not AF after follow-up. Common proteins of EAT secretome from patients with AF and those who develop AF are named in the right square **(A)**. Graph represents molecular function of identified proteins on EAT secretomes from AF patients and those who develop AF **(B)**.](fphys-11-00620-g002){#F2}

The comparison between patients with or without AF identified 488 common proteins and 93 proteins specifically in EAT secretomes from AF patients. After testing the common proteins between patients with AF or those who develop new-onset AF during follow-up, we found 17 proteins ([Figure 2A](#F2){ref-type="fig"}). Some of the identified proteins are typically expressed in neutrophils \[azurocidin (AZU1)\], in macrophages and inflamed tissues CD5 molecule like \[CD5L\], and in blood vessels \[cadherin-5 (CDH5) and tropomyosin (TPM2)\]. The rest of the proteins were mainly a compound of the extracellular matrix \[collagens 3 and 4 (COL3 and COL4, respectively), fibulin-2 (FBLN2), and laminin subunit alpha-5 (LAMA5)\]. Thus, after classifying proteins according their molecular functions, we observed that most of them were compounds of the extracellular matrix or cell adhesion junctions. But, also, we have to emphasize the presence of two proteins which are involved in immune defense (AZU1 and CD5L) ([Figure 2B](#F2){ref-type="fig"}). In addition, we have to highlight the presence of attractin (ATRN), which regulates the chemoattractant activity during the inflammatory response, in those patients who develop new-onset AF during follow-up.

Differential Levels Among EAT Biopsies, EAT Secretomes, and Plasma {#S3.SS2}
------------------------------------------------------------------

After identifying epicardial fat proteins, whose secretion is regulated by isoproterenol treatment, on patients with AF or AF during follow-up, we wanted to study their own expression levels on tissue. Because collagen (COL) ([@B12]) or fibulins (FBLNs) ([@B10]) were already described to be associated with AF, we decided to test CD5L in EAT biopsies from 15 patients (clinical characteristics in [Table 1B](#T2){ref-type="table"}). Our data showed that CD5L levels did not reach the difference with statistical significance between patients with and without AF or who suffered AF during follow-up (0.46 ± 0.56 vs. 0.24 ± 0.19). However, after splitting the population based on sex, we observed a higher levels in those male patients who had or developed AF (0.44 ± 0.05 vs. 0.18 ± 0.15; *p* \< 0.016) ([Figure 3A](#F3){ref-type="fig"}). Whereas it is secreted by isoproterenol on proteomics study, we confirmed by western blot the same result ([Figure 3B](#F3){ref-type="fig"}). We tried to test if CD5L plasma levels were modified with AF presence. We have included samples from 12 patients ([Table 1C](#T3){ref-type="table"}). However, we did not observe differences with statistical significance between patients with AF or those who develop AF during follow-up and those who are non-AF ([Figure 3C](#F3){ref-type="fig"}).

###### 

Clinical characteristics of tissue CD5L study with respect to A.

                                      **With AF or AFf (*n* = 9)**   **Without AF (*n* = 6)**
  ----------------------------------- ------------------------------ --------------------------
  Age years (SD)                      68 (10)                        66 (16); *p* = 0.788
  BMI, kg/m^2^ (SD)                   30 (6)                         31 (4); *p* = 0.938
  Heart rate (bpm)                    69 (15)                        69 (20); *p* = 0.995
  Gender (male/female)                4/5                            5/1; *p* = 0.138
  CAD (no/yes)                        2/7                            5/1; *p* = 0.020\*
  NYHA (I/II/III-IV)                  2/7/0                          1/3/2; p = 0.176
  T2DM (no/yes)                       7/2                            5/1; *p* = 0.792
  HTA (no/yes)                        5/4                            2/4; *p* = 0.398
  DLP (no/yes)                        5/3                            1/5; *p* = 0.086
  Aortic valve replacement (no/yes)   2/7                            2/4; *p* = 0.634
  Mitral valve replacement (no/yes)   7/2                            5/1; *p* = 0.796
  LVEF (%)                            55 (10)                        57 (22); *p* = 0.995
  Diuretics (no/yes)                  3/5                            2/4; p = 0,872
  β-Blockers (no/yes)                 5/3                            1/5; *p* = 0.086
  Statins (no/yes)                    5/3                            2/4; *p* = 0.280
  ACEi (no/yes)                       5/3                            4/2; *p* = 0.872
  ARB (no/yes)                        7/1                            3/3; *p* = 0.124
  Antiarrhythmic class III (no/yes)   7/1                            6/0; *p* = 0.369

BMI, body mass index; CAD, coronary artery disease; NYHA, New York Heart Association; T2DM, type 2 diabetes mellitus; HTA, hypertension arterial; DLP, dyslipidemia; LVEF, left ventricle ejection fraction; ACEi, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; AFf, AF during follow-up; AF, atrial fibrillation.

∗

p

\< 0.05 statistical significance.

![Box plots represent the CD5L levels in epicardial adipose tissue (EAT) biopsies from patients with sinus rhythm (SR) and atrial fibrillation (AF) or new-onset AF after follow-up **(A)**. Western blot for analyzing CD5L levels in EAT biopsies and supernatants from three patients after isoproterenol treatment **(B)**. Western blots for analyzing plasma CD5L levels in patients with SR or AF and new-onset AF after follow-up **(C)**.](fphys-11-00620-g003){#F3}

###### 

Clinical characteristics of plasma CD5L study with respect to AF.

                                      **With AF or AFf (*n* = 7)**   **Without AF (*n* = 5)**
  ----------------------------------- ------------------------------ --------------------------
  Age years (SD)                      66 (12)                        68 (13); *p* = 0.868
  BMI, kg/m^2^ (SD)                   33 (8)                         28 (5): *p* = 0.304
  Heart rate (bpm)                    66 (10)                        67 (17); *p* = 0.906
  Gender (male/female)                4/3                            1/4; *p* = 0.198
  CAD (no/yes)                        4/3                            2/3; *p* = 558
  NYHA (I/II/III-IV)                  0/4/3                          0/3/2; *p* = 0.921
  T2DM (no/yes)                       2/5                            4/1; *p* = 0.079
  HTA (no/yes)                        3/4                            2/3; *p* = 0.921
  DLP (no/yes)                        3/4                            3/2; *p* = 0.558
  Aortic valve replacement (no/yes)   3/4                            1/4; *p* = 0.408
  Mitral valve replacement (no/yes)   4/3                            3/2; *p* = 0.921
  LVEF (%)                            56 (8)                         66 (20); *p* = 0.333
  Diuretics (no/yes)                  2/4                            0/5; *p* = 0.154
  β-Blockers (no/yes)                 3/2                            3/1; *p* = 0.635
  Statins (no/yes)                    1/5                            3/2; *p* = 0.137
  ACEi (no/yes)                       4/2                            2/3; *p* = 0.376
  ARB (no/yes)                        4/2                            4/1; *p* = 0.621
  Antiarrhythmic class III (no/yes)   4/2                            5/0; *p* = 0.154

BMI, body mass index; CAD, coronary artery disease; NYHA, New York Heart Association; T2DM, type 2 diabetes mellitus; HTA, hypertension arterial; DLP, dyslipidemia; LVEF, left ventricle ejection fraction; ACEi, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; AFf, AF during follow-up; AF, atrial fibrillation.

∗

p

\< 0.05 statistical significance.

Discussion {#S4}
==========

For the first time, we identified epicardial fat mediators of AF, whose secretion is regulated by β-adrenergic stimulation, on patients with HF. The combination of HF and AF disease increments the death probability ([@B16]), in part, due to the fact that the high adrenergic activity contributes to its progression ([@B31]). Catecholamines have a binding site on the heart, skeletal muscle, and adipose tissue ([@B25]). The last one can be localized over the myocardium and incremented during obesity, being one of the major causes of ventricle dysfunction and atrial dimensions ([@B11]). Thus, adipokine regulation by adrenergic activity on adipose tissue might be involved in adverse consequences of the myocardium structure ([@B17]). In line with this, several of them were found to favor fibrosis ([@B29]; [@B8]) and AF. We mainly identified epicardial fat proteins involved in the extracellular matrix, inflammation, and cell adhesion. They were common in supernatants of epicardial fat from patients who developed AF during follow-up with or without AF prior to surgery. These results suggest proteins with a predictor and mediator role of AF which are regulated by catecholaminergic activity on epicardial fat. One of them, CD5L, was upregulated on EAT in patients with AF or those who develop AF. Its secretion by catecholaminergic stimulation might increase its paracrine effect over the myocardium or other adjacent tissues. In human atrial tissues, the higher presence of COL type 3 was associated with higher macrophage migration inhibitory factor (MIF) in patients with AF ([@B32]). Thus, fibrosis and inflammation lead to structural remodeling. Although we did not identify MIF as a differential factor, we detected CD5L. This protein, named the autophagy inhibitor macrophages, is a soluble receptor of macrophages that can be circulating at high concentrations in the blood with immunoglobulin M (IgM) ([@B21]). However, after testing their plasma levels, we did not find differences regarding AF. Thus, a local inflammatory effect on epicardial fat might explain the differences in plasma or tissue CD5L behavior. Even obesity, which is associated with a high macrophage infiltration in adipose tissue ([@B30]), might be a risk factor with an important contribution of CD5L levels on epicardial fat. It can also explain the identification of attractin protein, which is incremented in obesity, as a risk factor of new-onset AF. Thus, higher CD5L levels in plasma might be coming from the adipose tissue secretion induced by high catecholamine activity. We tried to corroborate this hypothesis, and CD5L was analyzed in supernatants ([@B10]) and biopsies from epicardial fat after catecholamine treatment. Our results confirmed the secretion of CD5L by EAT after isoproterenol treatment. This molecule might activate the toll-like receptor 4/nuclear factor-kappa B (NF-κB) pathway on the adjacent cells and the production of proinflammatory cytokines. Other identified proteins in EAT secretomes from patients with HF and AF were the COLs. It is known that their plasma levels were found to be biomarkers of AF ([@B3]). However, plasma CD5L was not an AF risk factor. Maybe, the combination of all identified proteins (markers of chemotactic activity, macrophage viability, neutrophil activity, adhesion, and extracellular matrix) will be useful for stratifying patients with high catecholaminergic activity in patients with EAT, HF, and AF. Some studies are trying to looking for proteomic chips as new biomarkers of AF risk ([@B15]) because HF is a syndrome with multiple involved pathways or mechanisms. However, several data regarding proinflammatory monocytes ([@B4]) or macrophage activity (CD5L) suggest the important role of inflammatory response of EAT on HF progression.

Limitations {#S5}
===========

This is a substudy of the previous one ([@B5]), and the sample size left with quality after 5 years' follow-up is too low. Quantification of CD5L was tested by a semiquantitative technique, western blot. A low percentage of patients developed new-onset AF during long-term follow-up. Plasma and tissue were obtained from different patients. Catecholamine levels on each patient were not analyzed or registered. AF asymptomatic was not detected or registered.

Conclusion {#S6}
==========

Although further studies are needed, our results suggest that CD5L levels in EAT are mediators of AF in male patients with HF. Further studies are needed to understand its paracrine role in the myocardium after catecholaminergic activity.
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